Myelodysplasia and transgene inactivation in X-CGD-γ retroviral gene therapy: The usual suspects and new players
- PMID: 37980903
- PMCID: PMC10727967
- DOI: 10.1016/j.ymthe.2023.11.007
Myelodysplasia and transgene inactivation in X-CGD-γ retroviral gene therapy: The usual suspects and new players
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
References
-
- Uchiyama T., Kawai T., Nakabayashi K., Nakazawa Y., Goto F., Okamura K., Nishimura T., Kato K., Watanabe N., Miura A., et al. Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD. Mol. Ther. 2023;31:3424–3440. - PubMed
-
- Braun C.J., Boztug K., Paruzynski A., Witzel M., Schwarzer A., Rothe M., Modlich U., Beier R., Göhring G., Steinemann D., et al. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci. Transl. Med. 2014;6:227ra33. - PubMed
-
- Stein S., Ott M.G., Schultze-Strasser S., Jauch A., Burwinkel B., Kinner A., Schmidt M., Krämer A., Schwäble J., Glimm H., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 2010;16:198–204. - PubMed
-
- Hinai A.A., Valk P.J.M. Review: Aberrant EVI1 expression in acute myeloid leukaemia. Br. J. Haematol. 2016;172:870–878. - PubMed
LinkOut - more resources
Full Text Sources
